<DOC>
	<DOCNO>NCT02227940</DOCNO>
	<brief_summary>This phase I trial study side effect best dose ceritinib combination chemotherapy treat patient solid tumor spread place body usually cure controlled treatment ( advanced ) pancreatic cancer spread start nearby tissue lymph node ( locally advance ) spread place body ( metastatic ) . Ceritinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride , paclitaxel albumin-stabilized nanoparticle formulation , cisplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving ceritinib one drug ( combination chemotherapy ) may better treatment solid tumor pancreatic cancer .</brief_summary>
	<brief_title>Ceritinib Combination Chemotherapy Treating Patients With Advanced Solid Tumors Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) recommend Phase II dose ( RP2D ) ceritinib combination gemcitabine ( gemcitabine hydrochloride ) alone , gemcitabine/nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) gemcitabine/cisplatin patient advance solid malignancy . SECONDARY OBJECTIVES : I . Characterize safety profile ceritinib combination gemcitabine base chemotherapy advance solid malignancy . II . Determine pharmacokinetic profile ceritinib , gemcitabine , nab-paclitaxel , cisplatin metabolite administer combination patient advance solid tumor . III . Determine preliminary efficacy study combination . TERTIARY OBJECTIVES : I . Explore potential biomarkers efficacy study combination . OUTLINE : This dose-escalation study ceritinib . Patients assign 1 3 treatment arm . ARM 1 ( ceritinib MTD gemcitabine alone ) : Dose Escalation Cohort 1 : Patients advance solid tumor gemcitabine hydrochloride-based therapy clinically appropriate receive ceritinib orally ( PO ) daily ( QD ) day 1-28 gemcitabine hydrochloride intravenously ( IV ) 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Expansion Cohort 1E : Once MTD ceritinib determine , additional 10 patient anaplastic lymphoma kinase positive ( ALK-positive ) advance solid tumor previously progress gemcitabine hydrochloride-based therapy receive ceritinib gemcitabine hydrochloride dose escalation cohort 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM 2 ( ceritinib MTD gemcitabine nab-paclitaxel ) : Dose Escalation Cohort 2 : Patients advance pancreatic cancer receive ceritinib PO QD day 1-28 , gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Expansion Cohort 2E : Once MTD ceritinib determine , patient ALK-positive advanced solid tumor receive ceritinib , gemcitabine hydrochloride , paclitaxel albumin-stabilized nanoparticle formulation dose escalation cohort 2 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM 3 ( ceritinib MTD gemcitabine cisplatin ) : Dose Escalation Cohort 3 : Patients advance solid tumor gemcitabine hydrochloride cisplatin-based therapy clinically appropriate receive ceritinib PO QD day 1-28 , gemcitabine hydrochloride IV 30 minute day 1 8 , cisplatin IV day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Expansion Cohort 3E : Once MTD ceritinib determine , additional 10 patient ALK-positive advanced solid tumor receive ceritinib , gemcitabine hydrochloride , cisplatin dose escalation cohort 3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow least 4 week .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Arm 1 : histologically cytologically confirm solid tumor advance gemcitabinebased treatment consider clinically appropriate option Arm 2 : histologically cytologically confirm adenocarcinoma pancreas locally advance metastatic Arm 3 : histologically cytologically confirm solid tumor advance gemcitabine plus cisplatin treatment consider clinically appropriate option Arms 1E , 2E 3E : solid tumor demonstrate anaplastic lymphoma kinase ( ALK ) positivity ; ALK positivity assess use assay , documentation ALK positivity use one test require Fluorescence situ hybridization ( FISH ) test ALK positivity use Food Drug Administration ( FDA ) approve FISH test ( Abbott Molecular Inc ) , use Vysis breakapart probe ( define 15 % positive tumor cell ) ; OR Harboring confirm ALK positivity , determine positivity Ventana immunohistochemistry ( IHC ) assay Arms 1E : previously treat progressed gemcitabinecontaining therapy Arms 1 , 2 , 3 : patient clinically measurable evaluable malignant disease Arms 1E , 2E , 3E : patient least one measurable site disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 previously irradiated Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Life expectancy &gt; = 3 month Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm^3 ( system international [ SI ] unit 1.5 x 10^9/L ) Platelets &gt; = 100,000 cells/mm^3 ( SI unit 100 x 10^9/L ) Hemoglobin &gt; = 9 g/dL ( SI unit 90 g/L ) ( absence transfusion within 24 hour prior dose ) Aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) alanine aminotransferase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) = &lt; 3 x upper limit normal ( ULN ) ; patient know hepatic involvement , AST ALT = &lt; 5 x ULN allow Total bilirubin = &lt; 1.5 x ULN Calculated measure creatinine clearance ( CrCL ) &gt; = 60 mL/min use modify Cockcroft Gault formula Serum lipase = &lt; 2 x ULN Serum amylase = &lt; 2 x ULN International normalize ratio ( INR ) = &lt; 1.5 ; ( anticoagulation allow target INR = &lt; 1.5 stable dose warfarin stable dose low molecular weight [ LMW ] heparin &gt; 2 week first dose study agent ) If urinalysis show proteinuria , 24 hour urine collection perform 24 hour urine protein &lt; 2 gram eligible Willing able comply schedule visit , treatment plan laboratory test Ability understand willingness sign write informed consent ; sign informed consent must obtain prior study specific procedure Patient must consent use archival tumor tissue protocol use available Arms 2 , 2E , 3 , 3E : patient previously receive &gt; 2 line systemic chemotherapy advance metastatic disease Previous pelvic radiation affect &gt; = 25 % bone marrow ; patient receive whole pelvic radiation exclude Patients receive last administration anticancer therapy include chemotherapy , immunotherapy , hormonal therapy monoclonal antibody ( exclude nitrosourea , mitomycinC , target therapy radiation ) = &lt; 4 week prior start study drug Patients receive last administration nitrosourea mitomycinC = &lt; 6 week prior start study drug Patients radiotherapy = &lt; 4 week prior start study drug , = &lt; 2 week prior start study drug case localize radiotherapy ( e.g. , analgesic purpose lytic lesion risk fracture ) Patients receive targeted therapy ( e.g. , sunitinib , sorafenib , pazopanib ) , except ALK inhibitor , = &lt; 2 week prior start study drug Patients residual toxicity ( ities ) previous anticancer treatment ( ) is/are clinically significant &gt; grade 1 exclude ; whose toxicity ( ities ) improve grade 1 well eligible The patient le 5 halflives prior ALK inhibitor target therapy ( adequate washout ) without recovery treatment toxicity &lt; grade 1 pretreatment level Patients know history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) Patients undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) , open biopsy significant traumatic injury = &lt; 4 week prior start study drug , patient minor procedure , percutaneous biopsy placement vascular access device = &lt; 1 week prior start study drug , recover side effect procedure injury Known hypersensitivity infusion reaction cisplatin gemcitabine Patients know hypersensitivity excipients ceritinib ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) Receiving medication meet one follow criterion discontinue least 1 week prior start treatment ceritinib duration participation : Medication know risk prolong QT interval induce torsades de pointes Strong inhibitor strong inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) /5 Medications low therapeutic index primarily metabolize CYP3A4/5 , cytochrome P450 , family 2 , subfamily C , polypeptide 8 ( CYP2C8 ) and/or cytochrome P450 , family 2 , subfamily C , polypeptide 9 ( CYP2C9 ) Therapeutic dos ( define dos need achieve target INR &gt; 1.5 ) warfarin sodium ( Coumadin ) Coumadinderived anticoagulant ; anticoagulant derive warfarin allow ( e.g. , dabigatran , rivaroxaban , apixaban ) Unstable increase dos corticosteroid Enzymeinducing anticonvulsive agent Herbal supplement Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study ; impaired cardiac function clinically significant cardiac disease , include follow : Unstable angina within 6 month prior screen Myocardial infarction within 6 month prior screen History document congestive heart failure ( New York Heart Association functional classification III IV ) Uncontrolled hypertension define systolic blood pressure ( SBP ) &gt; = 160 mm Hg and/or diastolic blood pressure ( DBP ) &gt; = 100 mm Hg , without antihypertensive medication Initiation adjustment antihypertensive medication ( ) allow prior screen Ventricular arrhythmia ; supraventricular nodal arrhythmia control medication Other cardiac arrhythmia control medication Corrected QT ( QTc ) &gt; 450 msec use Fridericia correction screen electrocardiogram ( ECG ) Any active gastrointestinal ( GI ) impairment , opinion investigator , would impair alter absorption ceritinib ( e.g. , ulcerative colitis , Crohn 's disease ) Ongoing GI adverse event &gt; grade 2 ( e.g. , nausea , vomit , diarrhea ) start study History alcoholism , drug addiction , psychiatric psychological condition , opinion investigator , would impair study compliance Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol Pregnant breastfeed woman Women childbearing potential , define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( e.g. , menses time precede 12 consecutive month ) , must negative serum pregnancy test = &lt; 3 day prior start study treatment Women childbearing potential , biologically able conceive , employ 2 form highly effective contraception ; male use least least one form highly effective contraception exclude ; highly effective contraception ( e.g . male condom spermicide , diaphragm spermicide , intrauterine device ) must use sex study must continue 3 month end study treatment ; oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study Patients untreated brain metastasis signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastasis ; patient brain metastasis definitively treat stable decrease dose steroid within 4 week start study treatment eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>